Cipla Limited. Q4 results show revenue fell from 5924.53 to 5873.93 crores, a 0.85% decrease in growth. EPS also dropped from ₹9.92 to ₹6.51, down by 34.38%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Cipla Ltd. shared its Q4 results on Friday. They earned 5873.93 crores in revenue this quarter, but that’s less than the 5924.53 crores they made last quarter. Unfortunately, the company’s growth decreased by 0.85 percent when comparing the two quarters.
In terms of profits, Cipla Ltd’s PAT (Profit After Tax) for this quarter was 525.65 crores, down from 800.96 crores in the previous quarter. Their quarter-to-quarter growth declined by 34.37 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹6.51, which is a decrease of 34.38% from the ₹9.92 EPS in the previous quarter.
Also read: ☞ ” APL Apollo Tubes Q4FY23 Results: Consolidated PAT Rises at Rs 201.82 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 23228.57 crores this year (2023), which is 5.37 percent higher than last year’s total revenue of 22044.25 crores.
This year’s PAT (Profit After Tax) is 2801.91 crores, which is also 11.33% higher than last year’s PAT of 2516.75 crores.
The EPS (Earnings Per Share) for this year is ₹34.69, which is 11.29% more than the EPS of ₹31.17 earned last year.
The company earns the most revenue from its retail and telecom segments, which are its two major revenue sources.
Cipla Share Dividend Announcement / Record Date:
The Board of Directors has declared a Final Dividend of ₹8.50 per Equity Share of Face Value of ₹2 each of the Company (425% of Face Value). Total Dividend for FY23 stood at ₹5 per Equity Share (Interim Dividend of ₹2 per Equity Share)
| Dividend | Record Date |
| ₹8.50 per Equity Share | Coming Soon |
The record date for the dividend has not arrived yet.
About Cipla:
Headquartered in Mumbai, Cipla Limited is a multinational pharmaceutical company with a focus on developing medications for a wide range of medical conditions such as respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and more.
Download Full PDF Q4 Results of Cipla: Click Here
For more of the Latest News, Click Here
2 thoughts on “Cipla Q4FY23 Results: Consolidated PAT Rises at Rs 525.65 Cr”